Fesoterodine for the treatment of overactive bladder

被引：0
|
作者：
Belavic, Jennifer M. [1 ]
机构：
[1] Univ Pittsburgh, Med Ctr Presbyterian, Trauma Intens Care Unit, Pittsburgh, PA 15260 USA
来源：
NURSE PRACTITIONER | 2009年 / 34卷 / 08期
关键词：
D O I：
10.1097/01.NPR.0000358655.33692.99
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
[No abstract available]
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [41] ECONOMIC IMPACT OF USING FESOTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER IN VULNERABLE ELDERLY POPULATION IN THE UNITED STATES
    Qin, L.
    Luo, X.
    Zou, K. H.
    Snedecor, S. J.
    [J]. NEUROUROLOGY AND URODYNAMICS, 2015, 34 : S412 - S413
  • [42] EFFICACY AND SAFETY OF FESOTERODINE TREATMENT FOR OVERACTIVE BLADDER (OAB) SYMPTOMS IN ELDERLY WOMEN WITH AND WITHOUT HYPERTENSION
    Yoshida, M.
    Hotta, S.
    Hiro, S.
    Yamagami, H.
    Yokoyama, O.
    [J]. NEUROUROLOGY AND URODYNAMICS, 2016, 35 : S294 - S295
  • [43] An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material
    Schneider, T.
    Arumi, D.
    Crook, T. J.
    Sun, F.
    Michel, M. C.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (09) : 1074 - 1080
  • [44] Flexible dose fesoterodine in the treatment of overactive bladder (OAB) (vol 112, pg 281, 2013)
    Tubaro, A.
    De Nunzio, C.
    [J]. BJU INTERNATIONAL, 2013, 112 (06) : E430 - E430
  • [45] Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review
    Chapple, Christopher
    Oelke, Matthias
    Kaplan, Steven A.
    Scholfield, David
    Arumi, Daniel
    Wagg, Adrian S.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (06) : 1201 - 1243
  • [46] Cost Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland
    Angulo, Javier C.
    Valpas, Antti
    Rejas, Javier
    Linden, Kari
    Kvasz, Marion
    Snedecor, Sonya J.
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (05) : 297 - 307
  • [47] Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms
    Van Kerrebroeck, P. E. V.
    Heesakkers, J.
    Berriman, S.
    Aiyer, L. Padmanabhan
    Carlsson, M.
    Guan, Z.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (05) : 584 - 593
  • [48] UPDATED ECONOMIC ANALYSIS OF FESOTERODINE RELATIVE TO TOLTERODINE AND SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER: THE SWEDISH PERSPECTIVE
    Lee, R.
    Snedecor, S. J.
    Kvasz, M. G.
    Trocio, J.
    Borgman, B.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A76 - A76
  • [49] Cost Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland
    Javier C. Angulo
    Antti Valpas
    Javier Rejas
    Kari Linden
    Marion Kvasz
    Sonya J. Snedecor
    [J]. Clinical Drug Investigation, 2014, 34 : 297 - 307
  • [50] EFFICACY AND TOLERABILITY OF FESOTERODINE FUMARATE IN THE TREATMENT OF OVERACTIVE BLADDER SYNDROME IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS
    Silvia, Proietti
    Emanuele, Lepri
    Luca, Lepri
    Carolina, Lolli
    Marilena, Gubbiotti
    Antonella, Giannantoni
    [J]. NEUROUROLOGY AND URODYNAMICS, 2012, 31 : S30 - S31
12345